Armored CAR T cells next on the production line



Park_Jae H_MD_NCCN_2014_240_v2.jpg
Jae H. Park, MD

Chimeric antigen receptor (CAR) T cells have “remarkable” activity, according to a speaker at the NCCN 9th Annual Congress: Hematologic Malignancies. “[T]his chimera binds like an antibody, but it acts like a T cell, so it combines the best of both worlds,” said Jae H. Park, MD, of Memorial... [Read Article]

Preventing cancer-related infection



hand-washing_Credit_CDC_Kimberly_Smith_Christine_Ford_220.jpg
Hand washing
Credit: CDC/Kimberly Smith
and Christine Ford

Hand washing is still the single most effective method to prevent the transmission of infection, but additional measures can reduce the risk of cancer-related infections, according to a speaker at the NCCN 9th Annual Congress: Hematologic Malignancies. In her presentation, Laura Zitella, RN, of the Stanford... [Read Article]

Speaker offers alternatives for sustainable TKI use in CML



Shah_Neil_MD_PhD_NCCN2014_strt-shrp-240.jpg
Neil P. Shah, MD, PhD

If any oncology drugs warrant a high price, BCR-ABL tyrosine kinase inhibitors (TKIs) could make a strong case, according to a speaker at the NCCN 9th Annual Congress: Hematologic Malignancies. TKIs have revolutionized the therapeutic landscape in chronic myeloid leukemia (CML), said Neil P. Shah, MD, PhD, of the UCSF... [Read Article]

Split decision on role of upfront transplant in MM



HSCs_being_prepared_for_transplant_credit_Chad_McNeeley_230.jpg
Preparing for transplant
Credit: Chad McNeeley

A debate on the pros and cons of upfront transplant in symptomatic multiple myeloma (MM) yielded a split decision from the audience during the NCCN 9th Annual Congress: Hematologic Malignancies. Sergio Giralt, MD, argued for upfront transplant, pointing out that long-term MM survivors have transplants upfront. Kenneth Anderson,... [Read Article]